STAB1 and leukemia: Since cell lines lack other immune cells that are present in the leukemic bone marrow and may contribute to bexmarilimab response, we treated the 34 AML and 4 MDS bone marrow samples ex vivo with bexmarilimab as a single-agent for 48 h and used flow cytometry profiling to study the effect of CLEVER-1 inhibition in primary leukemia and MDS cells.